Blog - Latest News
You are here: Home1 / Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. By Dr. Neal Shore2 / 3.27-AbirateroneAcetate
Contact
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572
Phone: (843) 839-1679
Fax: (843) 286-0119
Email:
info@curcmb.com
Recent Happenings
- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
- Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
- The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer
Our Affiliates
